<p><strong>Pregnancy</strong>&nbsp;Category C: Peginterferon alfa-2a monotherapy. There are no adequate and well controlled trial on pregnant women &amp; developing fetus due to teratogenic effects. Peginterferon alfa-2a is recommended for use in women of childbearing potential only when they are using effective contraception during therapy.<br />
<br />
<strong>Pregnancy&nbsp;</strong>Category X. It is not known whether peginterferon or ribavirin or its components are excreted in human milk. Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue peginterferon and ribavirin treatment.</p>